Preparation and Evaluation of Radiolabeled Antibody Recruiting Small Molecules That Target Prostate-Specific Membrane Antigen for Combined Radiotherapy and Immunotherapy
- 3 March 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (6), 2660-2673
- https://doi.org/10.1021/acs.jmedchem.5b01881
Abstract
The feasibility of developing a single agent that can deliver radioactive iodine and also direct cellular immune function by engaging endogenous antibodies as an antibody-recruiting small molecule (ARM) was determined. A library of new prostate-specific membrane antigen (PSMA)-binding ligands that contained antibody-recruiting 2,4-dinitrophenyl (DNP) groups and iodine were synthesized and screened in vitro and in vivo. A lead compound (9b) showed high affinity for PSMA and the ability to bind anti-DNP antibodies. Biodistribution studies of the iodine-125 analogue showed 3% ID/g in LNCaP xenograft tumors at 1 h postinjection with tumor-to-blood and tumor-to-muscle ratios of 10:1 and 44:1, respectively. The radiolabeled analogue was bound and internalized by LNCaP cells, with both functions blocked using a known PSMA inhibitor. A second candidate showed high tumor uptake (>10% ID/g) but had minimal binding to anti-DNP antibodies. The compounds reported represent the first examples of small molecules developed specifically for combination immunotherapy and radiotherapy for prostate cancer.Keywords
Funding Information
- Natural Sciences and Engineering Research Council of Canada
- Ontario Institute for Cancer Research
This publication has 25 references indexed in Scilit:
- Advances in targeted therapy for unresectable melanoma: New drugs and combinationsCancer Letters, 2015
- Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potentialTherapeutic Advances in Medical Oncology, 2014
- Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-PepPharmaceuticals, 2014
- Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human DiseaseACS Chemical Biology, 2012
- A Chemically Induced Vaccine Strategy for Prostate CancerACS Chemical Biology, 2011
- Synthesis and Biological Analysis of Prostate-Specific Membrane Antigen-Targeted Anticancer ProdrugsJournal of Medicinal Chemistry, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Chemical Control over Immune Recognition: A Class of Antibody-Recruiting Small Molecules That Target Prostate CancerJournal of the American Chemical Society, 2009
- A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urineThe Prostate, 2000
- Natural DNP-binding immunoglobulins and antibody multispecificityMolecular Immunology, 1984